Director Jessica Grossman gets 26,066 RSUs at Dare Bioscience (NASDAQ: DARE)

Rhea-AI Filing Summary

Grossman Jessica D. reported acquisition or exercise transactions in this Form 4 filing.

Dare Bioscience director Jessica D. Grossman received an equity grant instead of cash fees for her board service. She was awarded 26,066 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share.

Each restricted stock unit represents a right to receive one Dare Bioscience share when it vests. All 26,066 units vest on January 4, 2027, and this grant brings her directly held position from this award to 26,066 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grossman Jessica D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common stock	26,066	$0.00	--

Holdings After Transaction: Common stock — 26,066 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 26,066 shares Grant price: $0.00 per share Post-transaction holdings: 26,066 shares +1 more

4 metrics

RSU grant size 26,066 shares Restricted stock units granted for board service

Grant price $0.00 per share Stated price for RSU award

Post-transaction holdings 26,066 shares Shares held directly after this RSU grant

Vesting date January 4, 2027 RSUs fully vest on this date

Key Terms

restricted stock units ("RSU"), contingent right, vests

3 terms

restricted stock units ("RSU") financial

"Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation"

contingent right financial

"Each RSU represents a contingent right to receive one share when vested."

vests financial

"The RSUs vests on January 4, 2027."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:22 PM Accepted by SEC EDGAR 07/02/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Jessica D.

(Last) (First) (Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	06/30/2026		A		26,066(1)	A	$0	26,066	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.

Remarks:

	/s/ Sabrina Martucci Johnson, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dare Bioscience (DARE) director Jessica Grossman receive in this Form 4?

Jessica D. Grossman received 26,066 restricted stock units as equity compensation for serving on Dare Bioscience’s board and committees. Each unit converts into one share of common stock when it vests, giving her a future ownership stake instead of cash fees.

How many Dare Bioscience (DARE) shares are covered by Jessica Grossman’s RSU grant?

The grant covers 26,066 restricted stock units, each representing one share of Dare Bioscience common stock upon vesting. After this award, the filing shows she holds 26,066 shares related to this grant directly, reflecting only this specific compensation transaction.

What is the vesting schedule for Jessica Grossman’s Dare Bioscience (DARE) RSUs?

The 26,066 restricted stock units vest on January 4, 2027. Vesting means the units convert into actual Dare Bioscience shares that she can own, subject to any applicable company policies or restrictions remaining after that vesting date.

Did Jessica Grossman buy or sell Dare Bioscience (DARE) shares in this transaction?

She did not buy or sell shares on the open market; she acquired them as a grant. The Form 4 shows a non-cash award of 26,066 restricted stock units for board service, with a stated price of $0.00 per share for the grant.

Why did Dare Bioscience (DARE) grant RSUs instead of cash to Jessica Grossman?

The footnote explains the RSUs were granted in lieu of cash compensation for her board and committee service. This structure compensates her with potential future shares, aligning part of her compensation with Dare Bioscience’s stock performance over time.